Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4A | P27815 | 13/20 | 0.74 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | PDE1A | P54750 | 1/20 | 0.74 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.74 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583362 | 1.00 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2232240 | 0.90 | PDE4B (0.81) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2526722 | 0.88 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL20624715 | 0.88 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2531105 | 0.88 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2528137 | 0.86 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL12432086 | 0.86 | PDE4B (0.76) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL10186655 | 0.85 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL12431090 | 0.85 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4DCHRM1 | |
| SCHEMBL2527560 | 0.85 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4DCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-08-17 | — | — | US | claimed |
| EP-2343304-B1 | Biocidal boronophthalide compounds | ANACOR PHARMACEUTICALS INC (US) | 2015-06-10 | — | — | EP | claimed |
| US-20130244980-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | claimed |
| US-8440642-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | claimed |
| US-20110319361-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | claimed |
| EP-2343304-A1 | Biocidal boronophthalide compounds | Anacor Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | BT BIDCO, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240415806-A1 | METHODS OF TREATING PRADER-WILLI SYNDROME | LEVO THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12006329-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11957656-B2 | Methods of treating Prader-Willi syndrome | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-04-16 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7582621-B2 | Topically treating ungal and periungal infections of the nails, hoofs and claws of mammals by treating with 1-hydroxy-5-fluoro-1,3-dihydro-2,1-benzoxyborole; effectively penetrates the nail; onychomycosis; tinea unguium; fungicides; viricides; bactericides; parasiticides; yeast; microbiocides | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-2044091-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | Anacor Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146965-A2 | COMPOUNDS FOR THE TREATMENT OF PERIODONTAL DISEASE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | ANACOR PHARMACEUTICALS INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20060234981-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582809-B2 | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor | PDE4A, PDE1A, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 12/4885 |
| US-12006329-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PDE4B 4080/4885PDE4A 4020/4885PDE4C 4045/4885 |
| US-20170231931-A1 | PRODUCTS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS COURSING WITH A COGNITION DEFICIT OR IMPAIRMENT, AND OF NEURODEGENERATIVE DISEASES | SNCA, PSEN2, PSEN1 | PDE4B 1380/4885PDE4A 1415/4885PDE4C 1669/4885 |
| US-20060234981-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885 |
| US-20070286822-A1 | Compounds for the Treatment of Periodontal Disease | BPGM, HMBS, PPIP5K2 | PDE4B 1043/4885PDE4A 1049/4885PDE4C 1262/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | PDE4B 4080/4885PDE4A 4020/4885PDE4C 4045/4885 |
| US-20130244980-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20240358728-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885 |
| US-20070293457-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, TNF | PDE4B 1058/4885PDE4A 1336/4885PDE4C 2209/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | PDE4B 4080/4885PDE4A 4020/4885PDE4C 4045/4885 |
| US-20110319361-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.